Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACACIA RESEARCH CORPACTG · Entity 5559 | Director | March 15, 2017 | March 17, 2017 |
| ARROWHEAD PHARMACEUTICALS, INC.ARWR · Entity 3472 | Director | January 01, 2018 | January 04, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACACIA RESEARCH CORP
Report date March 15, 2017 · Filed March 17, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.40 · Expires 2024-03-15 | Direct | 54,299 |
Reported balance
After 2017-03-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-15 · Grant · Acquired 54,299 · Balance 54,299 F1: The option shares are exercisable in six equal installments over a three year period from March 15, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shares are exercisable in six equal installments over a three year period from March 15, 2017.
ARROWHEAD PHARMACEUTICALS, INC.
Report date January 01, 2018 · Filed January 04, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 148,852 |
Reported balance
After 2018-01-01 transaction · row 1
1 source rowRow 1 · 2018-01-01 · Grant · Acquired 25,000 · Balance 148,852 F1: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2018 Filed Jan 4, 2018 01:06 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-001573 · doc4.xml · nonDerivative · entry 1 FRYKMAN EDWARD W · CIK 0001078202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,852 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 22:15 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | GrantStock Option (Right to Buy) · Derivative | 54,299 | $0.00 Strike: $5.40 | $0.00 |
DisclosureSEC source: 0001078202-17-000003 · edgar.xml · derivative · entry 1 FRYKMAN EDWARD W · CIK 0001078202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,299 Underlying: Acacia Research Corporation Common Stock · 54,299 shares Expires 2024-03-15 F1 · derivative.exercise_date: The option shares are exercisable in six equal installments over a three year period from March 15, 2017. Read SEC document |
| January 01, 2017 Filed Jan 5, 2017 01:56 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-001625 · doc4.xml · nonDerivative · entry 1 FRYKMAN EDWARD W · CIK 0001078202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,852 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.